Rafael Pharmaceuticals Enters into Out-Licensing Agreement with Ono Pharmaceutical to Accelerate Clinical Development and Commercialization of Cancer Drug Candidate CPI-613® (devimistat) in Japan and Other Asian Countries

Stock Information for Rafael Holdings Inc. Class B

Loading

Please wait while we load your information from QuoteMedia.